Eli Lilly (LLY) Deferred Taxes (2009 - 2026)

Eli Lilly (LLY) has reported Deferred Taxes for 18 consecutive years, with $1.5 billion the latest figure, recorded in Q1 2026.

• Deferred Taxes for Q1 2026 came in at $1.5 billion, up 277.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.8 billion (changed 0.11% YoY), and the FY2025 annual result was $1.7 billion, down 36.38% from the prior year.
• Deferred Taxes was $1.5 billion for Q1 2026 at Eli Lilly, up from $748.1 million in the prior quarter.
• Over five years, Deferred Taxes peaked at $1.5 billion in Q1 2026 and troughed at -$501.4 million in Q3 2025.
• Average Deferred Taxes over 5 years is $611.4 million, with a median of $559.4 million recorded in 2023.
• Year-over-year, Deferred Taxes surged 4967.31% in 2023 and tumbled 216.66% in 2025.
• Over 5 years, Deferred Taxes stood at -$10.4 million in 2022, then soared by 4967.31% to $506.2 million in 2023, then jumped by 90.95% to $966.6 million in 2024, then decreased by 22.61% to $748.1 million in 2025, then surged by 97.57% to $1.5 billion in 2026.
• Per Business Quant data, the three most recent Deferred Taxes figures were $1.5 billion in Q1 2026, $748.1 million in Q4 2025, and -$501.4 million in Q3 2025.